When will ozempic patent expire?

Ozempic Patent Expiration Timeline

Ozempic, a medication primarily used to treat type 2 diabetes, is manufactured by Novo Nordisk [1]. The patent for Ozempic (semaglutide) expired on February 13, 2025, in the European Union (EU) region [2]. In the United States, the patent for Ozempic is scheduled to expire in June 2026 for the 2-mg/mL dosing strength and in December 2027 for the 0.5-mg/mL dosing strength due to pediatric exclusivity [3].

Generic and Biosimilar Versions

Generic and biosimilar versions of Ozempic are already available in various parts of the world, including several EU countries, Australia, and Canada. These versions have been manufactured by companies such as Teva Pharmaceuticals, Mylan, and Biocon [4]. In the United States, several biosimilar developers, including Pfizer, Boehringer Ingelheim, and Novartis, have received FDA approval for their versions of Ozempic [5].

Impact on Pharmaceutical Market

The expiration of the Ozempic patent is expected to lead to increased competition in the diabetes treatment market, potentially resulting in lower prices for the medication. However, generic and biosimilar manufacturers may face patent challenges from Novo Nordisk, who have filed patent lawsuits against companies attempting to market competing products [6].

References:

[1] Novo Nordisk, "About Ozempic" (https://www.novo-nordisk.com/about-ozempic/)

[2] European Medicines Agency, "Ozempic (semaglutide) (EU/1/14/1026/001)" (https://www.ema.europa.eu/en/medicines/human/MHpRs%3Fsearch=semaglutide)

[3] FDA, "Drug Patents and Exclusivity" (https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)

[4] DrugPatentWatch.com, "Ozempic (semaglutide) Patents and Exclusivity" (https://www.drugpatentwatch.com/drug/ozempic-semaglutide/)

[5] FDA, "Approved Biosimilar Products" (https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products)

[6] Novo Nordisk, "Patent Enforcement" (https://www.novo-nordisk.com/patent-enforcement/)

Note: The sources listed provide more in-depth information on the topic.